ClinicalTrials.gg
Active, not recruitingNCT04044443EMBO-PMSUpdated Dec 26, 2025

IMPEDE and IMPEDE-FX Embolization Plug Registry

An observational study in Peripheral Vascular Embolization, sponsored by Shape Memory Medical, Inc.. Active, not recruiting at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Shape Memory Medical, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
108
Ages
18 Years and older
Sex
All
01

Study summary

EMBO-PMS is a prospective, multicentre, registry study of the IMPEDE and IMPEDE-FX Embolization Plug Systems

02

Conditions studied

  • Peripheral Vascular Embolization
03

In context

Lead sponsor

Shape Memory Medical, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult study participants considered candidates for a peripheral vascular embolization procedure

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant is ≥18 years of age
  • Study participant is considered a candidate for arterial or venous embolization of the peripheral vasculature

Exclusion criteria

Exclusion Criteria:

  • Study participant has an inability to provide written
  • Study participant/treatment outside of the approved study device labeling, instructions for use (IFU)
  • Study participant is a prisoner or member of other vulnerable population
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
108 participants (actual)
Target follow-up
1 Year
Patient registry
Yes

Interventions

  • DeviceIMPEDE, IMPEDE-FX or IMPEDE-FX RapidFill

    Peripheral vascular embolization

06

What researchers measure

Primary outcomes

  1. Safety - Rate of freedom from serious adverse events

    Rate of freedom from serious adverse events related to the study devices and/or procedure, per review and adjudication by medical monitor

    Time frame: 30 days

  2. Efficacy - Rate of technical success (embolization of target vessel)

    Technical success, defined as embolization of the target area after deployment of the study device

    Time frame: Immediately after the intervention

Secondary outcomes

  1. Efficacy - Rate of recurrence of clinical symptoms, based on original complaint

    Number of participants free of recurrent clinical symptoms, based on clinical symptoms of original complaint

    Time frame: 90 days

  2. Efficacy - Rate of treated vessel occlusion

    Treated vessel occlusion, measured per study site standard of care for the original condition treated

    Time frame: 90 days

  3. Safety - Rate of freedom from serious adverse events

    Rate of freedom from serious adverse events related to the study devices and/or procedure, per review and adjudication by medical monitor

    Time frame: 90 days

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Aug 2025, 73 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2019
First posted
Aug 5, 2019
StartActual
Jul 9, 2019
Primary completionActual
Aug 30, 2025
CompletionEst.
Sep 2026
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04044443
Lead sponsor
Shape Memory Medical, Inc.
Responsible party
Sponsor
First posted
Aug 5, 2019
Start date
Jul 9, 2019
Primary completion
Aug 30, 2025
Completion
Sep 2026 (estimated)
Last update
Dec 26, 2025

Study contacts

Robert Morgan, MBChB
study chair · St George's Hospital (St George's University Hospitals NHS Foundation Trust)
Götz Richter
study chair · Klinikum Stuttgart

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion